The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.